Among them, four patients were treated with an ALK inhibitor, three of which showed a stable radiographic response and/or normalization of serum CA19-9.369 A phase 1 study to combine ceritinib, a novel ALK inhibitor, with chemotherapy for the treatment of advanced pancreatic cancer has just completed (NCT02227940). The gene discussed is ALK; the disease is pancreatic neoplasm.